Harmony Biosciences Holdings announced that Jeffrey M. Dayno will retire as President and Chief Executive Officer and step down as a Class I director effective December 31, 2026, serving as a non-executive advisor through January 2028. The Board appointed Senior Executive Vice President Peter Anastasiou to succeed Dr. Dayno as CEO and director, effective January 1, 2027. Mr. Anastasiou’s new compensation includes a $725,000 annual base salary, a target bonus of 75% of base, and initial equity awards valued at $2.5 million in aggregate. Dr. Dayno will receive severance per his existing agreements and hourly consulting fees of $500 during his advisory period. Harmony Biosciences is a biopharmaceutical company focused on developing treatments for rare diseases.
